




CV Template of KATRD International Conference 2021

Name	Nicolas Roche			
First Name	Nicolas	Last Name	Roche	
Country	France			
Organization	University of Paris Assistance Publique Hôpitaux de Paris			
Current Position	Professor of Respiratory Medicine, University of Paris and Head of the Respiratory Medicine Dept, Cochin Hospital, Paris, France			

Educational Background

- Masters (1991-1992): biostatistics, molecular biology
- M.D., Specialty in respiratory medicine: 1994,
- Ph. D, airway pharmacology, 2003
- Research Director Habilitation, 2003
- Assistant Professor, Respiratory Medicine: 2004
- Professor, Respiratory Medicine: 2008

Professional Experiences

- Head of the Respiratory Medicine department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (APHP) Centre, France
- Medical Director of the THOROS University Medical Department (Thorax, ENT, Sleep), APHP.Centre-University of Paris, France
- Professor of Respiratory Medicine, University of Paris, France
- Researcher, INSERM Research unit UMR 1016, Cochin Institute, Paris, France
- Associate researcher, Research Centre on Epidemiology and Population's Health, INSERM, Villejuif, France

Professional Organizations

RESEARCH GROUPS

France: Coordinator of:

- Initiatives COPD research group and cohort
- Respiratory consortium, French General Population cohort CONSTANCES, INSERM National Health Insurance.
- Respiratory committee, French patients cohort COMPARE, APHP.

International:

- Respiratory Effectiveness Group (REG) (Vide-President)
- ADMIT (Airways Drug Management Improvement Team)
- 3CIA consortium of COPD cohorts



SCIENTIFIC SOCIETIES

- European Respiratory Society:
 - Guidelines director, 2018-Sept 2021
 - Clinical Research Collaboration Working Group, 2017-Sept 2021
 - Council auditor, 2014-2016
 - Fellow of the ERS since 2016
- Past-President of the Société de Pneumologie de Langue Française (French Language Society of Respiratory Medicine)
- Vice-President (methodology), Respiratory Effectiveness Group
- Member of the American Thoracic Society

GUIDELINES

Member of the Scientific Committee, Global Initiative on Obstructive Lung Disease (GOLD)
Coordinator, French Language Society of Respiratory Medicine COPD guidelines
Coordinator, EAACI-REG taskforce on quality standards in comparative effectiveness asthma research

Member, ATS-ERS Taskforce on COPD research

Member, ERS Taskforce on alpha1 antitrypsin deficiency

Panel member, ATS guidelines on COPD exacerbations

Main Scientific Publications

5-year selection

1. Roche N. The need to increase awareness of the risk factors of COPD. *Expert Rev Respir Med* 2016; 10: 733–737.
2. Roche N, Dekhuijzen PNR. The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices. *J Aerosol Med Pulm Drug Deliv* 2016; 29: 311–327.
3. Franssen FME, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, García-Río F, Kearney MT, Kwon N, Lundbäck B, Rabe KF, Raillard A, Muellerova H, Cockcroft JR. Lung Function Abnormalities in Smokers with Ischemic Heart Disease. *Am J Respir Crit Care Med* 2016; 194: 568–576.
4. Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2016; 194: 541–549.
5. Dres M, Hausfater P, Foissac F, Bernard M, Joly L-M, Sebbane M, Philippon A-L, Gil-Jardiné C, Schmidt J, Maignan M, Treluyer J-M, Roche N. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1047–1056.
6. Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I, Nesme-Meyer P, Perez T, Paillasseur J-L, Pinet C, Jebrak G, Roche N, Burgel P-R. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1819–1824.
7. Caillaud D, Chanez P, Escamilla R, Burgel P-R, Court-Fortune I, Nesme-Meyer P, Deslee G, Perez T, Paillasseur J-L, Pinet C, Jebrak G, Roche N, Initiatives BPCO scientific committee and investigators. Asthma-COPD overlap syndrome (ACOS) vs “pure” COPD: a distinct phenotype? *Allergy* 2017; 72: 137–145.
8. Fuhrman C, Moutengou E, Roche N, Delmas M-C. Prognostic factors after hospitalization for COPD exacerbation. *Rev Mal Respir* 2017; 34: 1–18.



9. Jouneau S, Dres M, Guerder A, Bele N, Bellocq A, Bernady A, Berne G, Bourdin A, Brinchault G, Burgel PR, Carlier N, Chabot F, Chavaillon JM, Cittee J, Claessens YE, Delclaux B, Deslée G, Ferré A, Gacouin A, Girault C, Ghasarossian C, Gouilly P, Gut-Gobert C, Gonzalez-Bermejo J, Jebrak G, Le Guillou F, Léveiller G, Lorenzo A, Mal H, Molinari N, et al. Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de pneumologie de langue française (summary). *Rev Mal Respir* 2017; 34: 282–322.
10. Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. *Am J Respir Crit Care Med* 2017; 195: 1189–1197.
11. Zysman M, Chabot F, Housset B, Morelot Panzini C, Devillier P, Roche N, Société de Pneumologie de Langue Française. Pharmacological treatment optimisation for stable COPD: an endless story? Proposals from the Société de Pneumologie de Langue Française. *Eur Respir J* 2017; 50.
12. Burgel P-R, Paillasseur J-L, Janssens W, Piquet J, Ter Riet G, Garcia-Aymerich J, Cosio B, Bakke P, Puhan MA, Langhammer A, Alfageme I, Almagro P, Ancochea J, Celli BR, Casanova C, de-Torres JP, Decramer M, Echazarreta A, Esteban C, Gomez Punter RM, Han MK, Johannessen A, Kaiser B, Lamprecht B, Lange P, Leivseth L, Marin JM, Martin F, Martinez-Cambor P, Miravittles M, et al. A simple algorithm for the identification of clinical COPD phenotypes. *Eur Respir J* 2017; 50.
13. Roche N, Zysman M, Burgel P-R. Blood eosinophil counts as a guide for COPD treatment strategies. *Lancet Respir Med* 2018; 6: 78–80.
14. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet* 2018; 391: 1076–1084.
15. Campbell JD, Perry R, Papadopoulos NG, Krishnan J, Brusselle G, Chisholm A, Bjermer L, Thomas M, van Ganse E, van den Berge M, Quint J, Price D, Roche N. The REal Life Evidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. *Clin Transl Allergy* 2019; 9: 21.
16. Roche N, Campbell JD, Krishnan JA, Brusselle G, Chisholm A, Bjermer L, Thomas M, van Ganse E, van den Berge M, Christoff G, Quint J, Papadopoulos NG, Price D. Quality standards in respiratory real-life effectiveness research: the REal Life Evidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force. *Clin Transl Allergy* 2019; 9: 20.
17. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J* 2019; 53.
18. Roche N, Antoniadis A, Hess D, Li PZ, Kelkel E, Leroy S, Pison C, Burgel P-R, Aguilaniu B, COLIBRI COPD Research Group. Are there specific clinical characteristics associated with physician's treatment choices in COPD? *Respir Res* 2019; 20: 189.
19. Zysman M, Burgel P-R, Court-Fortune I, Brinchault-Rabin G, Nesme-Meyer P, Surpas P, Deslée G, Perez T, Le Rouzic O, Jebrak G, Chanez P, Paillasseur J-L, Caillaud D, Roche N, Initiatives BPCO scientific committee and investigators. Relationship between gender and survival in a real-life cohort of patients with COPD. *Respir Res* 2019; 20: 191.
20. Roche N, Aguilaniu B, Zhi Li P, Hess D, COLIBRI collaborators. Trends over time in COPD treatment choices by respiratory physicians: An analysis from the COLIBRI-COPD French



cohort. *Respir Med* 2019; 156: 8–14.

21. Roche N, Anzueto A, Bosnic Anticevich S, Kaplan A, Miravittles M, Ryan D, Soriano JB, Usmani O, Papadopoulos NG, Canonica GW, Respiratory Effectiveness Group Collaborators. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. *Eur Respir J* 2019; 54.

22. Roche N. Systemic Medications in Chronic Obstructive Pulmonary Disease: Use and Outcomes. *Clin Chest Med* 2020; 41: 485–494.

23. Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF. From GOLD 0 to Pre-COPD. *Am J Respir Crit Care Med* 2021; 203: 414–423.

24. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Roche N. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. *Eur Respir J* 2021; 57.

